Location:homepage  News  Research News

Research News

Small: New progress in cell-based drug delivery for tumor treatment
Submission:张灿课题组  Date:2019-01-07   Page View:11

Gastric cancer is one of the high mortality-rate cancers, and the life quality of patients is extremely poor for the limited benefit of  standard chemoradiotherapy and accompanied toxicity. We exploited our cell-loading technology platform to deliver chemotherapy drugs, and made the latest progress in the treatment of gastric cancer. Albumin-bound paclitaxel (Abraxane) is currently a second-line chemotherapy for gastric cancer. It has better curative effect and lower toxicity than traditional paclitaxel. Our team loaded albumin-binding paclitaxel (Abraxane) into neutrophils, combined with moderate radiotherapy for tumor treatment in which radiotherapy releasing inflammatory factors drived drug-loaded neutrophils targeting the cancer lesions and released cytotoxic drug.

This work expands the technology platform and application of cell-loaded drugs, providing new opportunities for the treatment of advanced cancer. The research was recently published in Small (IF 9.598) "Neoadjuvant Chemotherapy Based on Abraxane / Human Neutrophils Cytopharmaceuticals with Radiotherapy for Gastric Cancer". Dr. Caoyun Ju was the first author and  Professor Can Zhang was the Corresponding Author.

Neoadjuvant Chemotherapy Based on AbraxaneHuman Neutrophils Cytopharmaceuticals with Radiotherapy for Gastric Cancer.pdf